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Abstract
In Austria, vaccination coverage against Bordetella pertussis infections during infancy is
estimated at around 90%. Within the last years, however, the number of pertussis cases
has increased steadily, not only in children but also in adolescents and adults, indicating
both insufficient herd immunity and vaccine coverage. Waning immunity in the host and/or
adaptation of the bacterium to the immunised hosts could contribute to the observed re-
emergence of pertussis. In this study we therefore addressed the genetic variability in B.
pertussis strains from several Austrian cities. Between the years 2002 and 2008, 110 sam-
ples were collected from Vienna (n = 32), Linz (n = 63) and Graz (n = 15) by nasopharyngeal
swabs. DNA was extracted from the swabs, and bacterial sequence polymorphisms were
examined by MLVA (multiple-locus variable number of tandem repeat analysis) (n = 77), by
PCR amplification and conventional Sanger sequencing of the polymorphic regions of the
prn (pertactin) gene (n = 110), and by amplification refractory mutation system quantitative
PCR (ARMS-qPCR) (n = 110) to directly address polymorphisms in the genes encoding two
pertussis toxin subunits (ptxA and ptxB), a fimbrial adhesin (fimD), tracheal colonisation
factor (tcfA), and the virulence sensor protein (bvgS). Finally, the ptxP promoter region was
screened by ARMS-qPCR for the presence of the ptxP3 allele, which has been associated
with elevated production of pertussis toxin. The MLVA analysis revealed the highest level of
polymorphisms with an absence of MLVA Type 29, which is found outside Austria. Only Prn
subtypes Prn1/7, Prn2 and Prn3 were found with a predominance of the non-vaccine type
Prn2. The analysis of the ptxA, ptxB, fimD, tcfA and bvgS polymorphisms showed a geno-
type mixed between the vaccine strain Tohama I and a clinical isolate from 2006 (L517).
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The major part of the samples (93%) displayed the ptxP3 allele. The consequences for the
vaccination strategy are discussed.
Introduction
Bordetella pertussis, the causative agent of whooping cough, is still responsible for significant
morbidity and mortality in many countries of the world. Mainly in resource-poor regions,
every year 195,000 children, mostly unimmunised, are estimated to die from pertussis [1].
To control pertussis, whole cell vaccines (WCVs) were introduced in the 1940s and have
been replaced by the less reactogenic acellular vaccines (ACVs) in the 1980s. ACVs contain the
detoxified pertussis toxin (Ptx), filamentous hemagglutinin (FHA), pertactin (Prn) and fim-
briae (Fim) in various combinations. A recent review from the Cochrane Acute Respiratory
Infections Group [2] summed up six efficacy trials with a total of 46,283 participants. Multi-
component ACVs (n 3 components) had an efficacy between 84% and 85% in preventing
typical whooping cough. In contrast, the examined one- or two-component ACVs prevented
only between 59% and 75% of typical whooping cough, however, a new Danish monocompo-
nent ACV, containing only Ptx toxoid, was recently shown to achieve excellent 93% efficacy
against severe pertussis requiring hospitalisation [3]. The Cochrane Group also assessed 52
safety trials with a total of 136,541 participants to show that indeed the ACVs lead to signifi-
cantly fewer local and systemic adverse reactions than the WCVs [2].
In Austria, the pertussis vaccination coverage is estimated at around 90% for infant vaccina-
tion. A hexavalent vaccine is given including the pertussis ACV combined with vaccines
against diptheria, tetanus, polio, hepatitis B and Haemophilus influenzae type B. For booster
vaccination, a tetravalent vaccine without the two last components is given. In many affluent
countries like Austria, despite high pertussis vaccination coverage, increasing incidence rates
have been observed [4–8]. On the average, the most affected group was the 5–14-year-olds
with a confirmed case rate slightly higher than 11 per 100,000 population [9]. In Austria the
all-time low in the number of pertussis cases was in 1995 with only 91 reported cases (1.14 per
100,000 population) and since then these numbers have been increasing continuously up to
425 confirmed cases (5.06 per 100,000 population) in 2012 [9]. Although the disease in older
children is milder than in the infants, there are concerns that small children may be infected
before their first vaccination. In addition, severe pertussis cases have been increasingly
observed in the elderly population [7]. Consequently, it is important to understand and to try
to stop the re-emergence of pertussis cases.
Several causes are conceivable for the rise in incidence. The rise in awareness and improve-
ment of diagnostics could play a certain role, but probably this will be limited. More likely,
some cases of pertussis in older children and adults may not be diagnosed correctly, as the
symptoms may be atypical or mild, and since diagnostic procedures such as culture may have a
low sensitivity [10]. Another explanation is the waning protection [11,12] against B. pertussis
accompanied by waning antibody levels [13], which have been observed in children immunised
with ACVs.
A third explanation for the increasing pertussis prevalence would be that under the pressure
of vaccination, altered B. pertussis strains might emerge which would be less affected by the
immune reaction of vaccinated individuals. An early study [14] analysed a large Dutch pertus-
sis strain collection for their polymorphisms in the prn and ptxA genes. While the older strains
displayed the same gene variants as the vaccine strains, the newer strains collected between
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1990 and 1996 were predominantly non-vaccine types. As there were large differences in the
vaccination schedule and the composition of the vaccines at the time, a surveillance program
entitled “European Research Programme for Improved Pertussis Strain Characterization and
Surveillance (EUpertstrain)”was founded to monitor differences in the incidence of pertussis
and in the population structure of B. pertussis in Europe [15,16].
Few years later, a new method, multiple-locus variable-number tandem repeat analysis
(MLVA) was introduced [17] which examines highly polymorphic regions containing variable
numbers of tandem repeats (VNTRs). This method also showed that pre-1990 pertussis strains
were significantly more diverse than the strains isolated post-1990, and that some strains
expanded clonally during epidemic periods. MLVA (VNTR-typing) and sequence analysis of
the prn, ptxA, ptxC, and tcfA genes in 102 strains, isolated in the period from 1998 to 2001 in
Finland, Sweden, Germany, the Netherlands and France, revealed a relationship between
VNTR subtypes and geographic origin, but no relationship to vaccination programs was
observed [18].
In 2003, the B. pertussis genome was published and compared with the genomes of the less
pathogenic Bordetella parapertussis and Bordetella bronchiseptica [19]. In the search of further
polymorphisms between B. pertussis strains, the sequence of the older genome strain Tohama I
was compared with the strain L517 isolated in Australia in 2006 [20]. In total 70 single nucleo-
tide polymorphisms (SNPs) as well as five indels of 1–3 basepairs were detected. Five non-syn-
onymous base changes in virulence-associated genes were among the SNPs.
A major review [21] illustrates the low level of sequence variation in B. pertussis in general,
nevertheless, this review also cites 42 studies which describe polymorphisms and temporal
shifts in B. pertussis alleles in various countries. The most variable cell envelope component is
pertactin (Prn). The variations of Prn are confined to two regions, however. Region 1 contains
repeats comprising the pentapeptide elements GGAVP, GGFGP and GGGVP in eleven differ-
ent combinations, and in region 2, four more single amino acid polymorphisms are found.
Altogether there are 13 variants Prn1 to Prn13. An important variant of a non-protein coding
sequence is the ptxP3 allele which comprises a change in the pertussis toxin promoter region
which is associated with a higher expression of Ptx [22] and a number of other virulence fac-
tors, and with increased virulence. This strain was shown to expand significantly in the Nether-
lands so it could contribute to the pertussis resurgence [23].
The comparative genomic sequencing of two strains had revealed only one SNP per 20 kb
[20], and in total, polymorphisms were found in only 20 cell envelope- and virulence-associ-
ated proteins, so B. pertussis can be called a monomorphic pathogen [21]. Nevertheless, when
comparing different strains, but even after passaging the strain Tohama I in the laboratory,
large chromosomal rearrangements can be observed [24]. These can be caused by recombina-
tion of insertion sequence elements (ISEs). As an example, strain Tohama I contains 238 copies
of IS481 [19], corresponding to about 6% of its total genome. In strains from Finland [25] and
the Netherlands [26] isolated during the past decades, progressive gene loss was observed, with
lost loci flanked by IS481 elements, and the authors suggest that this could be a strategy of B.
pertussis to adapt to highly immunised populations. Moreover, strains from Belgium and the
Netherlands were discovered, in which the whole tcfA gene was deleted, presumably by recom-
bination also involving repeated sequences flanking the gene [27]. More recently, strains have
emerged which do not produce Prn, a component of most vaccines [28,29].
In the present study, we applied several methods to investigate gene polymorphisms in Aus-
trian B. pertussis isolates. Genotyping was done by means of MLVA analysis [17], Sanger
amplicon sequencing of the prn gene polymorphic region 1 [21], and ARMS-qPCR (amplifica-
tion refractory mutation system quantitative PCR) [30] for testing of five SNPs in virulence-
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associated proteins [20] and for identification of the ptxP3 allele associated with increased
expression of pertussis toxin [23].
Results
B. pertussis samples (n = 110) from patients aged from 1 month to 47 years were collected from
2002 to 2008 in three Austrian cities (Vienna, Linz, and Graz). The first part, collected from
2002 to 2006 (n = 77) was characterised by MLVA typing [17], and all samples (n = 110) were
examined by sequencing of the prn gene polymorphic region-1 [21], and ARMS-qPCR [30] of
target SNPs in the genes coding for pertussis toxin (ptxA and ptxB), fimbrial adhesin (fimD),
tracheal colonisation factor (tcfA), the virulence sensor protein (bvgS) [20], and the pertussis
toxin promoter region ptxP [22]. The detailed results can be found in S1 Table.
MLVA typing shows significant genotypic diversity of B. pertussis strains
in Austria
For the initial study on MLVA typing, 77 B. pertussis samples of infected patients with ages
between one month and 47 years (median 5.6 years of age) were collected from 2002 to 2006 in
three Austrian cities. Typing was successful for 34 of these samples. Seven different MLVA
types were identified (Table 1). The most common MLVA type was Type 27 with a frequency
of 67% (23/34) corresponding to the data from other European countries [18]. MLVA type 29,
which had been prevalent in other parts of Europe before 2000, was not found in any of the
Austrian samples. Instead, we detected various other MLVA types, i.e. Types 18, 36, 38, 63, 128
and 129 with frequencies between 3% and 12%. The genotypic diversity (GD) in the Austrian
B. pertussis population based on MLVA types was 0.56, similar to the GDs of the Swedish
(GD = 0.56), Dutch (GD = 0.52), French (GD = 0.51) and German (GD = 0.62) samples but
less than the GD of the Finnish (GD = 0.80) samples [18].
Analysis of prn polymorphisms in the Austrian samples shows three
variants
In this second part of the study, including the first 77 samples plus additional 33 samples from
Austrian patients (n = 110), the major polymorphic region 1 of the prn gene was PCR-ampli-
fied and 77 of the 110 B. pertussis samples could be sequenced successfully. Out of the 13
known Prn variants [21], only three, Prn1/7, Prn2 and Prn3 were found in Austria (Table 2).
The Prn2 variant predominated in strains isolated in all three Austrian cities with frequencies
of 64% (Graz), 72% (Vienna) and 76% (Linz). Overall, 56 of all 77 successfully analysed sam-
ples (73%) were characterised as Prn2. These data correspond to data from other European
countries where a dominance of the Prn2 variant was also observed [18,21]. Twelve percent of
Table 1. Variation of MLVA types in AustrianB. pertussis samples (n = 34) collected from 2002–2006.
Frequencies are given as numbers and as percentage of successfully typed samples (in brackets).
MLVA type Number and percentage
18 1 (3%)
27 23 (67%)
36 2 (6%)
38 4 (12%)
63 2 (6%)
128 1 (3%)
129 1 (3%)
doi:10.1371/journal.pone.0132623.t001
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the isolated Austrian strains had the Prn1/7 isotype and in 16% of the strains the Prn3 variant
was found (Table 2). We noted a small difference between these variants: whereas the Prn1/7
isotype was found in the whole sampling period, no more Prn3 samples were found after 2005.
Little diversity found in SNPs in genes coding for virulence-associated
factors
In order to include more polymorphisms in genes encoding virulence-associated factors, we
addressed the SNPs discovered by comparing the Tohama I and L517 strains [20] in the ptxA,
ptxB, fimD, tcfA and bvgS genes. All our samples (n = 110) were examined by ARMS-qPCR.
Surprisingly, the genotype of all the successfully analysed samples was a mixed one of bvgS,
fimD, ptxA, ptxB alleles as determined for strain L517 [20] and the tcfA allele as reported for
Tohama I [19]. The results of the individual samples are shown in S1 Table.
From one reference isolate from Linz (P11), we amplified the region around the SNPs and
performed classical Sanger sequencing. The obtained nucleotide sequences are available from
the NCBI database with the accession numbers JF990849 (ptxA), HM185483 (ptxB), JF990848
(fimD), HM185484 (tcfA), and JF990847 (bvgS). All sequences confirmed the previous results
of the ARMS-qPCR for the SNPs. In all cases except ptxA, no additional sequence variations
were found: The bvgS sequence was 100% identical to strains 18323, CS and BP165, and dis-
played only one SNP, G489-A, compared to the Tohama I strain. The fimD sequence was 100%
identical to strains 18323 and CS, with a single SNP, C138-T, compared to the strain Tohama
I. The ptxB sequence was identical to strains BP165, 18323 and 3779, whereas strains CS,
B1917, B1920, B1834, B1831, and Tohama I displayed one SNP A87-G. Finally the tcfA
sequence has been sequenced more frequently, our sequence was identical to 46 strains includ-
ing Tohama I and had SNPs with five strains. In contrast, the ptxA sequence displayed slightly
more polymorphisms, the A490-G SNP was found in strains B1917, B1920, B1834 and B1831.
In strain BP165 and strain 3779 there was another SNP from A192-G. In strain CS and
Tohama I there were two SNPs A490-G and A192-G. Strain 18323 displayed three SNPs,
T94-C, A192-G and A204-G.
High prevalence of the ptxP3 allele in the pertussis toxin promoter region
Finally, we examined our samples for the presence of the ptxP3 allele, possessing the base
“A”in the ptxA promoter region in position -65 relative to the transcriptional start site [22]. All
other ptxP alleles (here called ptxP1-like) contain the base “G”in this position. Strains carrying
the ptxP1 allele such as the strain Tohama I express lower levels of Ptx than the ptxP3 strains
which have become more prevalent in recent years [23].
Table 2. Genomic variations in prn variants of AustrianB. pertussis samples (n = 77) collected from
2002–2008. Frequencies are given as numbers and as percentage of successfully typed samples (in
brackets).
City Prn1/71 Prn2 Prn3
Vienna (n = 25) 5 (20%) 18 (72%) 2 (8%)
Graz (n = 11) 1 (9%) 7 (64%) 3 (27%)
Linz (n = 41) 3 (7%) 31 (76%) 7 (17%)
Total (n = 77) 9 (12%) 56 (72%) 12 (16%)
1To distinguish the prn variants Prn1 and Prn7, the sequence of the second polymorphic region is needed
as well.
doi:10.1371/journal.pone.0132623.t002
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We used ARMS-qPCR to test for the ptxP3 and ptxP1-like alleles in our samples (S1 Table).
In total, we found the ptxP3 allele in as many as 71 out of 76 amplified samples (93%). Only
five of the amplified samples (7%) carried the ptxP1 allele. Interestingly, four out of these five
were of the Prn1/7 isotype. The ptxP1 samples were from Linz (two samples from 2007) and
Vienna (three samples from 2003).
Discussion
In Austria, similar to many other countries with routine vaccination programs against pertus-
sis, the disease is far from eradication, and the number of cases has been increasing since the
year 1995. To explain this rising prevalence, one of the current hypotheses is that under vaccine
pressure B. pertussismay adapt slowly via the selection of mutant strains. The aim of this study
was to examine DNA polymorphisms in B. pertussis strains found in the Austrian population.
The first method applied (n = 34 samples analysed successfully) was MLVA typing [17]
which addresses regions with DNA repeats. As observed before, this method revealed the high-
est level of polymorphisms. MLVA Type 27 dominated as seen in other countries during a sim-
ilar sampling period [18]. MLVA Type 27 has seven repeats of the VNTR6 sequence, whereas
Type 29 has nine repeats of this sequence [17]. The sequence VNTR6 is found in a pseudogene
of a membrane protein, so the difference between the MLVA types does not appear to be
related to a difference in an expressed protein. Nevertheless, the relative prevalence of MLVA
Types 27 and 29 changed drastically during the past decades. In isolates from the United King-
dom, MLVA Type 29 had been found frequently towards the end of the last century, but had
slowly disappeared thereafter [31]. This change was associated with decreasing prevalence of
strains carrying the allele ptxP1 in the pertussis toxin promoter region, and increasing preva-
lence of ptxP3 strains expressing higher levels of Ptx [32]. In the light of these findings, it is not
surprising that no more MLVA Type 29 was found in our Austrian specimen collected between
2002 and 2006.
In the genes coding for vaccine antigens, variable region-1 of the prn gene is the region with
the highest sequence diversity [14] and this region was examined by PCR amplification fol-
lowed by conventional Sanger sequencing (n = 77 successfully determined). In total, 13 variants
of prn had been found [21], but in our study, only the variants Prn1/7 (n = 9), Prn2 (n = 56),
and Prn3 (n = 12), and none of the variants Prn4–Prn6 and Prn8–Prn13 were found, with
Prn2 strongly dominating (72%). As we had amplified and sequenced only the variable region-
1, the variants Prn1 and Prn7 could not be distinguished as they differ only in one base position
in the variable region-2.
The increase in the prevalence of Prn2 pertussis strains is associated with the re-emergence
of this pathogen in many countries, from Argentina and France [33,34], the USA [35], the
United Kingdom [36], the Netherlands [14], France [34], Poland [37], Finland and Sweden
[38], to Russia [39]. Unexpectedly, Australia [40] and Japan [41] turned out to be an exception
with the Prn1 variant dominating, but in Australia this situation changed drastically in the
2008–2010 epidemic when 86% of the samples were found to be Prn2 variants [42].
A further important recent change is the rising prevalence of the virulent ptxP3 strains with
a predicted higher expression of Ptx [23]. The vast majority (93%) of the tested Austrian sam-
ples, which had been collected between 2002 and 2008, carried the ptxP3 allele. The remaining
five ptxP1-like samples were from 2003 and 2007, their number is too small to conclude a
decrease over time.
During the 2008–2010 epidemic in Australia [42], 84% of the samples displayed the ptxP3 /
Prn2 combination. Similarly, 77% of our Austrian samples were analysed as ptxP3 / Prn2.
Whereas in Australia, only 2% of the ptxP3 samples were non-Prn2 variants [42], 16% of the
Bordetella pertussis in Austria
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Austrian samples were ptxP3 / Prn3 and 1% ptxP3 / Prn1. Taken together, our analysis
showed that in Austria the ptxP3 / Prn2 strains represent the majority as was found in many
other countries around the world. Nevertheless, other variants were present at a significant
percentage.
Taken together, our data agree with a number of findings from other countries. B. pertussis,
a monomorphic pathogen [21] displays only limited variability on the level of SNPs, so
addressing some of these failed to reveal any variability. A higher variability is always found in
repetitive elements such as the pentapeptide repeats of Prn in the variable region-1 and the
repeats addressed by the MLVAmethod. Although the rate of changes is not high, the changes
need to be monitored carefully. The availability of whole genome sequences will facilitate the
identification of additional polymorphic regions. Two examples for this approach are the anal-
ysis of six additional B. pertussis genomes including four ptxP1 and two ptxP3 strains [43], and
the whole genome sequence analysis of as many as 343 strains by Illumina technology [44]
which revealed a number of further interesting polymorphisms, that should be included in
future studies. As the strains in the latter study covered a long period of 90 years and were
from many countries, an overall picture of the strain evolution could be provided [44]. One of
the results of the study was the absence of a geographical clustering of strains, apparently B.
pertussis strains such as the newly evolved ptxP3 lineage spread rather rapidly. Therefore it is
not surprising that our Austrian results reflect many developments from other countries such
as the high prevalence of the Prn2 isotype and ptxP3 allele or the absence of MLVA Type 29 in
samples from the recent years. Although in the global comparison of the 343 strains [44] the
average density of SNPs was found to be one SNP per 770 bp, it was higher in the virulence-
associated than in the housekeeping genes, demonstrating the potential of B. pertussis to slowly
escape from vaccine pressure.
Among the Austrian pertussis patients with known immunisation status (n = 46), 74% had
not been vaccinated, and this remains the main risk factor for aquiring the disease. Within
each group of the major genotypes, the MLVA isotype 27, the Prn2 isotype and the ptxP3 iso-
type, 80% of the patients had not been immunised. Though not being the main focus of our
study, we also compared the ages of the patients that had suffered from pertussis in spite of
being immunised with those patients that had not been immunised (Fig 1). The median age of
immunised patients was 10 years, and of unimmunised patients only 0.5 years, significantly
lower (p<0.005). If the immunised individuals get the disease later than the unimmunised
ones, it goes to show that the immunisation works, but there is also a waning immunity.
In order to limit the further spread of pertussis in a population with high vaccine coverage,
the first remedy would therefore be a booster vaccination at school entry (6 years) to counteract
the waning of antibody levels. Additionally, regular booster vaccination every 10 years during
adulthood, followed by every 5 years after the age of 60 are strongly recommended by the Aus-
trian Advisory Committee on Immunization [45], but this new strategy has not yet been
broadly implemented.
Materials and Methods
Ethics statement
The samples collected from pertussis patients during an extended time period were taken as
part of routine diagostics and not for the purpose of this study. We obtained aliquots and
strictly anonymised patient information limited to age, and where available, whether the
patients had received an immunisation including pertussis. For this type of surveillance, ethical
evaluation or patient consent are not required.
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Study sites and collection of samples
Pertussis patients were diagnosed as suffering from cough for at least 14 days, in addition one
of the following symptoms: paroxysmal cough, inspiratory whoop, or posttussive vomiting
[46]. A total of 110 B. pertussis samples were collected from 2002 to 2008 in three Austrian
cities (Vienna (n = 32), Linz (n = 63), and Graz (n = 15)). Only the first part of these samples
collected from 2002 to 2006 (n = 77) was studied by MLVA typing. All 110 samples including
33 samples collected later were characterised in the other parts of this study. Bacterial DNA
was isolated from nasopharyngeal swabs of B. pertussis infected patients using the QIAamp
DNAMini Kit according to the manufacturer’s protocol (Qiagen, Hilden, Germany).
Multiple-Locus Variable-Number Tandem Repeat Analysis (MLVA)
Six VNTRs, (VNTR1, VNTR3a, VNTR3b, VNTR4, VNTR5 and VNTR6) were PCR-amplified
by using forward primers 5´-labelled with 6-carboxyfluorescein and unlabelled reverse primers
as reported [17] with bacterial DNA isolated from B. pertussis infected patients serving as tem-
plate. The amplification products were analysed with an ABI Prism 3100 Genetic Analyzer
(Life Technologies) at VBC Biotech, Vienna, Austria. The number of repeats found at the six
VNTR loci translates into a distinct MLVA type (www.mlva.net/).
Fig 1. Age distribution of immunised (n = 9) and unimmunised (n = 27) pertussis patients. The
immunisation status of the patients was unknown in many cases (see S1 Table).
doi:10.1371/journal.pone.0132623.g001
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Sanger sequencing of prn alleles
So far, 13 prn alleles have been identified with variation mainly limited to two regions [14]. For
our study, region 1 was chosen for sequencing as most variations are found therein. Primers
were designed as described [14] and are displayed in Table 3. The prn gene was PCR-amplified
from bacterial DNA isolated from B. pertussis infected patients. A second PCR with the ampli-
con of the first PCR as the template was used to increase the sensitivity. The first PCR reaction
(10 μl volume) consisted of 1× PCR Buffer (Qiagen) containing 1.5 mMMgCl2, 1× Q-Solution
(Qiagen), 300 μM of each dNTP (Thermo Scientific), 0.5 μM of each primer (PrnAF and
PrnAR [14]), 1 μl bacterial genomic DNA and 0.5 units HotStarTaq DNA Polymerase (Qia-
gen). The reaction was incubated at 95°C for 15 min, followed by 30 cycles of 94°C for 10 s,
50°C for 45 s and 72°C for 1 min, and final elongation at 72°C for 10 min. In the second PCR
(30 μl volume), 1.5 μl of the 100-fold diluted amplicon of the first PCR were used as input.
Cycling conditions were the same as for the first PCR, except for the number of cycles (45 cyles
instead of 30) and the annealing temperature (62°C instead of 50°C). PCR cycling was per-
formed in a Mastercycler gradient (Eppendorf, Hamburg, Germany).
The amplicon was purified using the QIAquick PCR Purification Kit according to the man-
ufacturer’s protocol. The amplification primers were used for Sanger sequencing of both DNA
strands (GATC Biotech, Konstanz, Germany).
Amplification refractory mutation system quantitative PCR (ARMS-
qPCR) to detect alleles of ptxA, ptxB, fimD, tcfA and bvgS genes as well
as the ptxP3 and ptxP1-like alleles
ARMS-qPCR [30], uses a SNP-specific primer having a specific base at the penultimate or last
position of the 3´-end and mismatching one or two bases upstream of this specific nucleotide
with the two (or three) sequences at the SNP site. This design strongly reduces unspecific
primer extension resulting in a limit for SNP discrimination of down to 0.1% [47]. ARMS-
qPCR was performed in the hydrolysis probe detection format. Tm values were calculated by
means of the software Primer Express 2.0 (Life Technologies). The Tm of ARMS primers is
given for the completely matching sequence (Table 3).
Singleplex qPCR for detecting the target SNPs in ptxA, ptxB, fimD, tcfA and bvgS genes was
performed in a 15 μl reaction in 96-well plates using the StepOnePlus Real Time PCR System
running under software version 2.0 (Life Technologies). The reaction contained 1 × PCR buffer
B2 (Solis Biodyne, Tartu, Estonia), 4.5 mMMgCl2, 0.2 mM of each dNTP, 250 nM consensus
primer, 150 nM ARMS primer, 150 nM hydrolysis probe, 1 U HOT FIREPol DNA Polymerase
(5 U/μl, Solis Biodyne), and 8 ng DNA. In the case of the tcfA gene having a high GC content
of 70%, the mastermix was supplemented with 1 × Solution S (Solis Biodyne). Initial denatur-
ation for 15 min at 95°C was followed by 3 cycles at 95°C for 20 s and 66°C for 55 s, 3 cycles at
95°C for 20 s and 65°C for 55 s, 3 cycles at 95°C for 20 s and 64°C for 55 s, finally 60 cycles at
95°C for 20 s and 65°C for 55 s.
The 10 μl duplex qPCR for differentiating the ptxP3 and ptxP1-like alleles contained
5 × HOT FIREPol Probe qPCR Mix Plus (no ROX) (Solis Biodyne), 250 nM of each primer,
100 nM of each hydrolysis probe, and 1.5 μl template DNA. Amplification performed on the
ViiA 7 Real-Time PCR System (Life Technologies) was started by an initial denaturation for
10 min at 95°C, and followed by 50 cycles at 95°C for 15 s, 58°C for 25 s, and 60°C for 25 s.
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Table 3. Primers and probes used in this study. A, Primers prnAF (top) and prnAR (bottom) [14] were used for prn sequencing.B, C-1, ARMS-qPCR prim-
ers for the determination of the ptxA, ptxB, fimD, bvgS and tcfA alleles (B) as well as for the discrimination between the ptxP1-like and ptxP3 alleles (C-1).
For each gene, the forward primer is shown on top, then the reverse primer corresponding to the Tohama I sequence and the reverse primer corresponding
to the alternative allele, with the base at the SNP site underlined, and finally the labelled hydrolysis probe. Lower case letters, artificial base replacement with
both sequences at the SNP site; FAM, 6-carboxyfluorescein; TET, 4,5,6,7-tetrachlorofluorescein; BHQ1, Black Hole Quencher-1; Cy5, red sulfoindocyanine
dye. C-2, oligonucleotides for the fimD non-discriminatory control assay.
Gene 5’ Nucleotide position1 Sequence Length [bp] Tm [°C] Amplicon length [bp]
A: PCR primers for sequence analysis of prn alleles [14]
prn 55187 GCCAATGTCACGGTCCAA 18 57 586
55772 GCAAGGTGATCGACAGGG 18 56
B: Oligonucleotides for typing the ptxA, ptxB, ﬁmD, and tcfA alleles by ARMS-qPCR
ptxA 160397 AACCCCTACACATCGCGAAGGT 22 63 73
160469 CGCCTATCACCGGCcCC 17 63
160469 CGCCTATCACCGGCcCT 17 60
160445 Cy5-CCAATGTGCCGACGATCGACGC TACG-BHQ1 26 74
ptxB 160878 CCATCGTAGAGCGCAAATATTG 22 58 148(+1)2
160731 AACAGATTACCCAGCATGtCC 21 53
160730 GAACAGATTACCCAGCATGtCA 22 56
160765 FAM-CTGCGCGAACAAGACCCGTG CC-BHQ1 22 72
ﬁmD 250435 CGGCCGCAGTCCTATGG 17 60 65(+1)2
250500 GGTCTCCTCCGTGGAGCaGA 20 61
250499 GTCTCCTCCGTGGAGCaGG 19 59
250453 FAM-CATCCGGGCATCGTGGTCGA CTTGC-BHQ1 25 74
tcfA 221437 GGTTGCCCGGTATAGGAAAGGT 22 61 134
221570 ATCCTTGCCCGCCCaAC 17 60
221570 ATCCTTGCCCGCCCaAT 17 60
221513 FAM-CATGGCGTCCGGAGCGG-BHQ1 17 66
bvgS 232055 CGACTCGCTGGGCGAACT 18 61 92
231964 CCTTGGCGTCGTGCAGaTT 19 61
231964 CCTTGGCGTCGTGCAGaTC 19 61
232025 FAM-CGGCGGCTGGATCGACATCA CCG-BHQ1 23 75
C: Duplex qPCR for typing of ptxP3 and ptxP1-like alleles
1 –ARMS-qPCR assay
ptxP 159628 CTACTGCAATCCAACACGGC 20 58 68(+1)2
ptxP1-like 159695 GACGGTGACCGGTtCCA 17 57
ptxP3 159696 GGACGGTGACCGGTtCTA 18 55
159655 TET-CTCCTTCGGCGCAAAGTCG CG-BHQ1 21 70
2 –Consensus (non-discriminatory) control assay
ﬁmD 250434 CCGGCCGCAGTCCTATG 17 60 113
250546 CCTTCTGCATCGGCGAACT 19 60
250453 FAM-CATCCGGGCATCGTGGTCGA CTTGC-BHQ1 25 74
1The nucleotide numbering refers to the numbering from the Tohama I genome [19]. Segment accession numbers: BX640414 (prn), BX640422 (ptxP,
ptxA, ptxB), BX640416 (ﬁmD and bvgS) and BX640414 (tcfA).
2The “colder”primer forming only two hydrogen bonds at the speciﬁc base has a one base extension at its 5´-end to compensate the reduced Tm.
doi:10.1371/journal.pone.0132623.t003
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Statistical analysis
Genotypic diversity (GD) based on MLVA typing was calculated by the equation: GD = [n/(n-
1)](1-∑xi
2), where xi is the frequency of the i
th DNA type and n is the number of strains
[18,48,49].
The age distributions between immunised and non-immunised patients were compared by
means of the two-tailed Wilcoxon–Mann–Whitney test.
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